People who have inherited BRCA mutations and are at high risk for cancer recurrence may benefit from a PARP inhibitor.
by Pamela Rafalow Grossman
After adapting remote patient monitoring programs to cancer patients with COVID-19, cancer centers delve deeper into the programs’ value for cancer patients undergoing treatment.
by Jon Kelvey
The FDA recently expressed a new commitment to testing cancer drugs at lower doses, rather than defaulting to the highest dose most people can tolerate.
by Marcus A. Banks
From the Editor-in-Chief
Research is leading to treatments that target cancer’s support system.
by William G. Nelson, MD, PhD
Forward Look
Cellular immunotherapies can offer periods when people do not require treatment.
by Christina Bennett
Most people who opt out of breast reconstruction are satisfied with their decision but are not always supported by their surgeons.
by Kris Conner
Over a decade after human papillomavirus vaccines first became available in the U.S., their effect on cervical cancer incidence is becoming apparent.
by Carisa D. Brewster
Using fecal transplants to improve immunotherapy response
by Natalie Slivinski
Tumor testing can help determine whether certain cancers are likely to respond to immunotherapy drugs.
by Kendall K. Morgan
The rapid development of mRNA COVID-19 vaccines could spark advances in similar treatments for cancer.
by Stephen Ornes
Patients now have full access to their online medical records. What are the benefits and downsides?
by Jen Tota McGivney
Authors make a call for anti-racist cancer research.
AACR Dialogues showcase honest discussion about delivering equitable care.
AACR's blog writers provide coverage of the AACR Annual Meeting 2021.
Learning Medicare’s ABCDs
donate to the AACR